Inclisiran, marketed under the brand name Leqvio® by Novartis in partnership with The Medicines Company (acquired by Novartis), has emerged as a groundbreaking RNA interference (RNAi) therapeutic for managing hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). With its biannual dosing regimen and proven efficacy in reducing LDL cholesterol, Inclisiran is rapidly gaining global traction. As demand grows, understanding the global buyers list for Inclisiran—including national health systems, pharmaceutical distributors, hospital networks, and private insurers—has become essential for manufacturers, suppliers, healthcare providers, and investors. This article provides a comprehensive, SEO-optimized overview of Inclisiran’s global procurement landscape, compliant with Google’s E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness) guidelines and focused on delivering high-value, accurate, and…